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Endocrine glands secrete peptide hormones that bind to specific receptors, and elicit a 
response.  In the pituitary, prohormone convertases (PC) PC1/3 and PC2 convert inactive 
prohormones into biologically active peptide hormones.  Proopiomelanocortin (POMC) is 
a precursor molecule that proteolytically cleaves at paired basic residue sites, and 
produces smaller biologically active peptides, such as adrenocorticotropic hormone 
(ACTH), α−melanocyte stimulating hormone (α−MSH), and β-endorphin.  β-endorphin 
is an endogenous opioid peptide hormone that plays a vital role in the body’s 
physiological response to stress, fear, and anxiety.  Morphine is an exogenous opioid, 
used for the treatment of moderate to severe pain and competes with β-endorphins when 
binding to µ−receptors located on the surface of target cells.  Opioids have a high abuse 
potential leading to the development of tolerance and dependence. The purpose of this 
research is to analyze the effects of morphine on prohormone processing by examining 
the β-endorphin peptide hormone spectrum using a Protein Chip Array technology with 
Surface Enhanced Laser Desorption Ionization Time of Flight Mass Spectrometry 
(SELDI- TOF-MS).  Brain extracts (amygdala, nucleus accumbens, periaqueductal gray, 
lateral hypothalamus, arcuate nucleus, and paraventricular nucleus) from normal rats (n= 
4-6) treated with morphine (75mg/day) or placebo pellet for 24 hours or a seven day 
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treatment were examined in this study. The protein (1ug/uL) was applied to a Weak 
Cation Exchange (WCX2) ProteinChip, air-dried, and coated with alpha-cyano-4-
hydroxy cinnamic acid (CHCA) matrix. SELDI-TOF MS (Ciphergen, LaJolla, CA) was 
used to analyze the peptide hormone spectrum for changes in peptide expression or 
processing levels.  The results showed that morphine modulates β-endorphin processing 
at 7 days.  Previous studies have shown that PC2 enzyme is primarily responsible for 
processing β−endorphin1-31 in mice. We conclude that PC2 is down-regulated, which may 
play a role in regulating the amount of active hormone to prohormone. This process may 
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I. INTRODUCTION AND PURPOSE 
 
The Endocrine System  
 The endocrine system is composed of hormone-secreting glands and organs.  
Hormones are chemical messengers released into the bloodstream that bind to the 
receptors of specific cells located in different regions of the body (Saladin, 2004).  The 
target cell is usually located away from the initial point of release and activates a 
biological response.  For example, hormones released from the pituitary region of the 
brain may act upon cells in the adrenal glands resulting in cortisol secretion. 
 Peptide hormones are synthesized as larger, biologically inactive precursors called 
preprohormones.  The signal peptide of the preprohormone is cleaved by enzymes in the 
endoplasmic reticulum (ER) to form a prohormone.  The prohormone is cleaved yielding 
a biologically active peptide hormone (Figure 1). 
Pro-opiomelanocortin (POMC) is cleaved by prohormone convertase 1 (PC1/3) 
and prohormone convertase 2 (PC2) enzymes which yield a biologically active β-
endorphin peptide hormone.  The body produces natural opioid peptides, such as β-
endorphin, in a response to combat stress and relieve pain. Exogenous morphine use may 
signal a decrease in the production of β-endorphin, thus decreasing the body’s ability to 
cope with stress. Heroin, an illegal derivative of morphine, is highly addictive. The abuse 
of heroin could lead to fatal overdose, spontaneous abortion, collapsed veins, and 
intravenous users risk contracting infectious diseases, including HIV/AIDS and hepatitis 
(National Institute on Drug Abuse, 2000).  Besides the medical consequences of heroin 
use, the abuser also suffers socially and economically. The results of this study may 
improve upon the existing knowledge that could potentially lead to the development of 
more effective pain relievers as well as develop better treatments for drug abusers.  
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The purpose of this research is to analyze the effects of morphine on prohormone 
processing by examining the β-endorphin peptide hormone spectrum by using Protein 
Chip Array technology with Surface Enhanced Laser Desorption Ionization Time of 
Flight Mass Spectrometry (SELDI- TOF-MS). This peptide spectrum can be used to 






Figure 1: Formation of Peptide Hormones Peptide hormones are derived from unique 
prohormones that are synthesized as pre-prohormones and proteolytically cleaved into 
active peptides. The diagram shows the hormone processing of pro-opiomelanocortin 
(POMC); the signaling peptide (SP) has been cleaved to form an active peptide. 




II. BACKGROUND  
Anatomy of Hypothalamic-Pituitary-Adrenal Axis 
 The hormones released between the hypothalamus, pituitary, and a distant 
endocrine gland are called an axis.  Three axes exist including the HP-gonadal axis, the 
HP-thyroid axis, and the HP-adrenal axis.   The research for this project is based upon the 
latter of these. 
Maintaining homeostasis within the body is achieved by the hypothalamus’ ability 
to control the endocrine and autonomic nervous system.  The hypothalamus regulates 
many functions including metabolism, heart rate, blood pressure, appetite, thirst, body 
temperature, sleep rhythms, memory, and emotional responses (Snell, 1992). 
Efferent projections are sent to the brain stem, forebrain, spinal cord, and anterior 
pituitary from the hypothalamus.  Distinct clusters of neurons located within the 
hypothalamus are known as nuclei. The nuclei can be divided into four anatomic regions: 
the preoptic, supraoptic, tuberal, and mamillary regions. A single nucleus may produce 
several hypothalamic hormones (Table 1).  The paraventricular (PVN) nuclei are 
composed of magnocellular neurons and located adjacent to the third ventricle and 
ventromedial to the fornix.  In addition, another group of nuclei of interest, the arcuate 
nucleus (ARC), lies ventral to the third ventricle and paraventricular nuclei (Figures 2 
and 3).  The median eminence, amygdala, preoptic area, ventro-medial nucleus, and 
capillaries of the median eminence and portal system contain β-endorphin, our peptide of 






Table 1: Biologically active substances located in the Arcuate and Paraventricular 
nucleus neurons (Melmed, 1995). 
 
Arcuate Nucleus Paraventricular nucleus  
Acetylcholine Angiotension II 
Dopamine Cholecystokinin 
Galanin Glucagon 
Gamma-Aminobutyric acid Oxytocin 
Growth hormone-releasing hormone Peptide 7B2 
Neuropeptide Y Proenkephalin B (dynorphin, rimophin, alpha- neo endorphin) 
Neurotensin Vasopressin 
Pancreatic polypeptide  












Figure 2: Coronal View of Rat Brain 
Representative schematic diagram of four of the six rat brain regions analyzed in this 
study.  The number in the bottom right hand corner represents the distance (mm) from the 
bregma in the rat brain atlas (Paxinos, 2007).  AMY, amygdala; LH, lateral 







Figure 3: Nucleus Accumbens and Periaqueductal Gray Representative schematic 
diagram of the nucleus accumbens, NA, and the Periaqueductal gray, PAG, two of the six 
rat brain regions analyzed in this study.  The number in the bottom right hand corner 





 The pituitary gland, also known as the hypophysis, is about 1.3 cm in diameter.  
This gland is connected to the hypothalamus by a stalk, the infundibulum, located 
between the optic chiasm and the mammillary bodies.  The pituitary is divided into two 
main parts: the anterior (adenohypophysis) and the posterior (neurohypophysis) 
(Thibodeau, 2003).  The hypothalamus and the pituitary are triggered by environmental 
stimuli that promote the generation of several hormonal responses in other endocrine 
glands.  The hypothalamus also produces and secretes releasing and inhibitory hormones 
that regulate the anterior pituitary hormones. The highest concentration of β-endorphin 
orphin and other proopiomelanocortion (POMC) derived peptides are located in the 
arcuate nucleus of the hypothalamus (Smith and Funder, 1988). 
 
Anterior Pituitary 
 The anterior pituitary also referred to as the adenohypophysis comprises three-
fourths of the hypophysis.  The anterior pituitary is divided into three parts: 1) the pars 
tuberalis, a small aggregate of cells that adhere anteriorly to the infundibulum; 2) the 
pars distalis, the large lobe most distal from the infundibulum; 3) pars intermedia, a strip 
of tissue located between the anterior and posterior lobes of the pituitary.  The pars 
intermedia is also referred to as the intermediate lobe and can be distinguished during 
human fetal development, but is not well defined in adult humans.  In contrast, the 
intermediate lobe can be seen in mouse models (Saladin and Porth, 1998).  The 
intermediate lobe is formed from the posterior limb of Rathke’s pouch behind the medial 
cleft of the pituitary. 
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Six peptide hormones are produced in the anterior pituitary: Thyroid Stimulating 
Hormone (TSH), Prolactin (PRL), Luteininzing Hormone (LH) Growth Hormone (GH), 
Follicle-Stimulating Hormone (FSH) and pro-opiomelanocortin, the precursor to 
Adrenocorticotrophic hormone (ACTH) and β-endorphin.  
 
Pro-Opiomelanocortin (POMC)  
POMC is the 266 amino acid gene precursor to ACTH and β-lipotropin (β-LPH).  
ACTH is formed inside corticotroph cells which are ovoid (angular) shaped and compose 
15-20% of the human anterior pituitary (Doniach, 1985).  The human POMC gene is 
located on chromosome 2p23 (Zabel et al., 1983).  The promoter region consists of 400 
base pairs followed by three exons and two introns. (Figure 4 ).  The POMC gene can be 
divided into three main regions or domains. Domain I is comprised of the N-terminal 
glycopeptide which encodes for γ-melanotropin (γ-MSH) and includes the joining 
peptide. Domain II contains ACTH which encodes, α-MSH, and corticotrophin-like 
intermediate lobe peptide (CLIP). Domain III is the C-terminal end of the gene where β-
lipotropin (β -LPH) is further processed into γ−LPH, β -MSH, and β-endorphin (β-end) 
(Imura, 1985).  The N-terminal glycopeptide, α-MSH, ACTH, and β-endorphin regions 
of Exon 3 are more than 95% identical between humans and other mammals (Eberwine 







Figure 4:  Human Proopiomelanocortin (POMC) gene and peptide fragments. 
The signaling peptide is cleaved from the preprohormone forming, a biologically active  
prohoromone. The POMC gene is protelytically cleaved into three domains. β-lipotropin 
is located at the C-terminal end of the POMC gene where it is processed into biologically 






Figure 5: Comparison of Synthesis of β-endorphin Rat, Mouse, and Human POMC 
Gene  The dots indicate there is no change in the amino acid sequence between rat and 
mouse. A letter indicates the change in amino acid between species. There is no 
difference in the β-endorphin region of the POMC gene amino acid sequence in rat or 




POMC peptides are mostly synthesized in the anterior pituitary corticotrophs, but 
can also be found in the dominant cell population of the intermediate pituitary, the 
melanotrophs.  However, in the soma of the infundibular nucleus (arcuate nucleus of 
rodents) ACTH and its related peptides are highly expressed (Bugnon et al., 1979; Parker 
et al., 1981).  POMC gene products are also located in nonpituitary human tissues such as 
the adrenal, testes, spleen, kidney, ovary, lung, thyroid, liver, colon, duodenum, and 
epidermis.(Buzzetti et al., 1989; DeBold et al., 1988; Rousseau et al., 2007) 
 
POMC Processing and Regulation  
Endocrine and neuroendocrine cells have a special pathway for the secretion of 
peptide hormones, i.e. the regulated secretory pathway (RSP) (Figure 6).  The regulated 
secretory pathway requires a stimulus in order for mature secretory granules (MSG) to be 
released into the bloodstream.  Corticotrophin releasing hormone (CRH) and cyclic 
adenosine monophosphate (cAMP) increases POMC messenger ribonucleic acid 
(mRNA) and peptide synthesis. In contrast, glucocorticoids inhibit transcription of 
POMC mRNA.  In the intermediate lobe, GABA, an inhibitory neurotransmitter causes a 
decrease in POMC mRNA levels, but not in anterior pituitary corticotrophs (Melmed, 
1995).  
POMC mRNA translation starts at the first AUG codon within the cytoplasm of free 
ribosomes and includes a 26 amino acid signal peptide that directs the emerging peptide 
into the endoplasmic reticulum (ER) where the signal recognition particle (SRP) binds to 
the SRP receptor on the ER.  The pre-prohormone continues into the lumen of the ER 
where a signal peptidase cleaves the signal peptide allowing the remainder of the POMC 
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precursor to relocate into the trans-Golgi network (Melmed, 1995).  Furthermore, the 
pre-prohormone is sorted away from the constitutive proteins and packaged into 
immature secretory granules (ISG).  
During the cleavage process, the immature secretory granules become mature 
secretory granules and are stored inside of the cell until depolarization of the cell 
membrane.  Depolarization causes an influx of Ca2+, and release of the peptide hormone 
into the bloodstream.  Therefore, the regulated secretory pathway is a secretagogue or 
stimulus-dependent release process.  After their release, the peptide hormones bind to 
receptors on target cells and elicit a response.  The hormones are degraded by lysosomes 
located within the target cell (Burgess et al., 1985). 
POMC derived peptides undergo glycosylation, C-terminal amidation, N-terminal 
acetylation, and phosphorylation. α− MSH and β-endorphin specifically undergo N-
terminal acetylation where acetyl coenzyme A is the acetyl donor. N-terminal acetylation 
of β-endorphin eliminates opiate activity (Melmed, 1995).  In contrast, N-terminal 
acetylation of ACTH increases melanotrophic activity in the intermediate pituitary and 





Figure 6: Regulated and Constitutive Secretory Pathways Peptide hormones are 
formed from the regulated secretory pathway. Prohormones are synthesized in the 
endoplasmic reticulum (ER) moved into the trans-Golgi apparatus network (TGN) forms 
immature secretory granules (ISG) that are processed by enzymatic cleavage into mature 
secretory granules (MSG) and finally released into the blood stream after depolarization 
of the cell membrane. Figure adapted from Loh YP et al., 1997. 
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Prohormone Convertases 1 and 2 
The processing of prohormones into biologically active peptide hormones 
requires prohormone converting enzymes.  In the hypothalamus and pituitary, these 
hormones have been identified as Prohormone Convertases (PC) 1 (also identified as 
PC3) and PC2, which were discovered in 1989-1990 (Steiner, 1998).  They are members 
of the subtilisin family of serine endoproteases, and are contained in secretory vesicles 
that emerge from the trans-Golgi network during the regulated secretory pathway (Seidah 
and Chretien, 1997).   
The proteolytic processing of POMC initiates in the trans-Golgi apparatus and 
continues in the secretory vesicles (Melmed, 1995).  PC1/3 is located in the anterior and 
intermediate pituitary lobes, and cleaves POMC to produce ACTH and γ-LPH.  PC1/3 is 
activated in the secretory granules, during prohormone processing where a more acidic 
pH exists.  The PC1/3 catalytic domain comprised of 753 amino acids contains an 
asparagine that plays an important role in stabilizing the cell.  In contrast, PC2 contains 
an aspartic acid in its 638 amino acid catalytic domain.  This amino acid difference may 
explain why the PC2 enzyme requires 7B2 protein to move the proPC2 from the 
endoplasmic reticulum into the trans-Golgi network (Muller, L., Zhu, X., Linderg, I., 
1997).  7B2 prevents autocatalytic cleavage of proPC2 in the more neutral pH 
environment of the Golgi.  PC2 can then be activated in the maturing secretory granules 
where a more acidic pH exists (personal communication, Friedman April 2007).  PC2 is 
mostly found in the intermediate lobe and proteolytically produces α-MSH and β-
endorphin (Figure 7).  
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PC1/3 and PC2 mRNA are both expressed in corticotroph cells, and both cleave 
POMC at paired basic residues i.e. Lys-Arg or Arg-Arg. There is no difference in the β-
endorphin region of the POMC gene amino acid sequence in rat or mouse and only two 
amino acid difference in human (Figure 8).  
 The conversion of β-LPH to β-endorphin in the hypothalamus and amygdala 
(AMY) is impaired in mice lacking the PC2 enzyme.  This impairment causes β-
endorphin1-31 to increase in these brain regions, due to the decrease of PC2 cleavage of 
carboxyl terminal-shortening of β-endorphin1-31.  The amount of unprocessed POMC also 
increased.  Altering PC1/3 and PC2 levels may contribute to the abnormal physiology 
observed in drug addiction because these enzymes mediate the physiologic processing of 











Figure 7: Mouse Pro-opiomelanocortin Processing. The solid arrows indicate 
previously known cleavage sites by PC1/3 and PC2. The dotted arrows are possible 





Pain is an unpleasant sensory and emotional experience that is associated with either 
actual or potential tissue damage, which varies widely in intensity, quality, duration, and 
persistence. (Merskey, Harold and Bogduk, N., 1994; Wallace, Mark S. and Staats, Peter 
S., 2005) Four distinct types of pain have been identified: nociceptive, inflammatory, 
neuropathic, and functional.  Pain must exist in humans for 3 months before it can be 
diagnosed as chronic.  The appropriate use of pain medication has the potential to restore 
enjoyment to a person’s life. 
The physiology of pain occurs through four processes: transduction, transmission, 
modulation, and perception.  Signals from the skin are carried to the nervous system and 
brain by sensory neurons known as nocicpetors.  Two major nociceptors exist: 
unmyelinated small diameter thus slow conducting C-fibers that transmit dull and 
burning pain, and myelinated fast conducting Aδ fibers that are medium to large in 
diameter and conduct prickling pain (Ito S., Okuda-Ashitaka E., Minami T., 2001).  
Throughout the transmission route, electrochemicals modify the original signal to 
amplify or inhibit it.  The junction of the peripheral and central nervous system, the 
dorsal horn, and the ascending and descending tracts to and from the brain are significant 
areas where modulation occurs.  Pain medications target these areas in order to reduce 
signal amplification.  The brain receives the signal, compares it to previous experiences, 
and responds to the stimulus.  This process is called perception.  The periaqueductal gray 
(PAG), located in the midbrain, modulates pain by inhibiting the neurons of the dorsal 
horn.  The amygdala (AMY) is involved in the emotional aspects of pain such as fear and 
autonomic responses to a threat.  The paraventricular nucleus (PVN) processes pain and 
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is located within the hypothalamus. The expression of ACTH and β-endorphin coincide 
with areas of the brain that mediate analgesia (Pilcher et al., 1988). In this study the PAG, 
AMY, PVN, Arcuate nucleus (ARC), Nucleus Accumbens (NA), and the lateral 
hypothalamus are examined. 
 
Opioids 
Opioids are analgesic compounds prescribed for the treatment of moderate to severe 
pain. (Table 2) Opioids are natural or synthetic chemicals based on the opium plant’s 
active component, morphine, and works by mimicking the body’s natural pain-relieving 
chemicals, β-endorphin. Opioids also classified as narcotics are generally prescribed for 
postsurgical pain relief as well as relief of cough and diarrhea (Wallace, Mark S. and 
Staats, Peter S., 2005) (Table 3).  They modulate pain, stress, fear, anxiety, and help to 
maintain homeostasis. 
Opioids can be full agonists, partial agonists, and mixed agonist-antagonists (Table 
4). When opioids bind to specific receptors they block the perception of pain.  Opioids 
can cause constipation, drowsiness, and may depress breathing resulting in death 
(National Institute on Drug Abuse, 2007).  Persons given opioids have the potential to 
develop tolerance and dependence to the drug which leads to abuse of the drug.  Several 
mechanisms exist whereby opiates act to alter nocicpetive transmission even within a 
single brain region.  Opioid receptors that modulate pain behavior are found in several 
brain regions including the PAG, cerebral cortex, nucleus accumbens (NA), thalamus, 
and brainstem (Melmed, 1995). 
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Mu (µ), delta (δ), and kappa (κ) are three distinct classes of opioid receptors that 
mediate the actions of endogenous and exogenous opioids.  Drugs acting on the kappa 
receptors only produce a mild degree of dependence while drugs acting at the mu-
receptors are highly addictive (Cowan, A., 1990).  Morphine has a high affinity to 
µ−receptors, but also binds with less affinity to the delta δ and kappa κ receptors 
(Kieffer, 1999).  These receptors are located in the brain, spinal cord, and gastrointestinal 
tract.  Three major peptide classes exist within the endogenous opioid family 
enkephalins, dynorphins, and endorphins which are derived from three precursor 





Table 2: Chemical Structures of Morphine-like Opioids 
 
Morphine  
                                     (Kadian)  
Diacteylmorphine     
                                                 (Heroin) 
Hydromorphone      
                                      (Dilaudid) 
    Codeine 
Oxycodone  
                                      (Oxycotin) 
      Hydrocodone  
                                             (Vicodin) 
         Propoxyphene  





































- - 5 
Propoxyphene Darvon Capsule - - 65 
Hydrocodone Vicodin, Lortab Tablet,expectorant 
elixir,suppository 
- - 5-10 
Hydromorphone Dilaudid Tablet,syrup,liquid 
IM,IV, SC, 
suppository 
1.3 3-5 4-8 
Meperidine Demerol Tablet,syrup,IM, 
IV,SC 
































Morphine  MS-Contin, 
Oramorph, 
Kadian 





   
Oxycodone Oxycotin, 
Percocet 
   
Propoxyphene Darvon    
Hydrocodone Vicodin, Vicodin 
tuss Lortab 
   
Hydromorphone Dilaudid    




Pharmacology of Morphine 
Morphine is derived from the seed pod of Papaver somniferum (poppy) plant. It 
can be given intramuscularly, orally, and rectally.  An intramuscular dose of morphine for 
a human is 10 mg given every 3-6 hours.  The starting oral dose is 20-60 mg and is 
available in 8-12h sustained-release tablets, 12-24 hour sustained- release capsules, and 
as a suppository (Abramowicz, 2000).  There is no optimal or maximal dose for morphine 
when used to treat chronic pain in humans. The appropriate dose is one that relieves pain 
throughout its dosing interval without causing unmanageable side effects. Morphine has 
been used to block nociceptive response in an unanesthetized rat, rabbit, cat, dog, and 
primate (Wallace, Mark S. and Staats, Peter S., 2005).    
The absorption rate of morphine varies upon the route of administration. 
Morphine binds to opiate receptors in the central nervous system and gastrointestinal 
tract, causing inhibition of ascending pain pathways, altering the perception of and 
response to pain, and produces generalized depression of the central nervous system. 
Metabolism of morphine occurs in the liver after conjugation with glucuronic acid 
forming morphine-3-glucuronide, morphine-6-glucuronide, and other minor metabolites 
(University of Maryland Medical Center, 2007).  After 72 hours, 90% of a single 
morphine dose is eliminated in the urine primarily as morphine-3-glucuronide. However, 
less than 10% is excreted unchanged (National Highway Traffic Safety Administration, ). 
Morphine may modify the body’s natural endogenous opioid system exacerbating the 





Morphine’s Impact on the Endocrine System  
Studying agents that affect the regulation of PC1/3 and PC2 may give more 
insight into the processing of prohormone and bioactive hormone systems.  Morphine 
alters the prohormone processing enzymes that activate prohormones.  The regulation of 
PC1/3 and PC2 expression by morphine is mediated through the mu-opioid receptor and 
requires intact cyclic adenosine monophosphate (cAMP) response elements (CREs) on 
the promoter.  cAMP response element binding protein (CREB) is a transcription factor 
that binds to CREs and plays an important role in drug dependence. Altering CREB 
levels changes the activity of prohormone convertases (PCs).  PC1/3 and PC2 promoter 
activity can be modified by agents that alter intracellular cAMP. Acutely administered 
morphine causes a decrease in intracellular cAMP and subsequently causes a decrease in 
PC expression. Conversely, in some regions of the brain, chronic morphine causes an 
increase in cAMP and thus, an increase in PC expression.  
 Friedman and colleagues demonstrated acute morphine administration in rats 
decreases PC1/3 and PC2 mRNA enzyme levels in hypothalamus and pituitary. Acute 
morphine administration in vivo also decreased POMC processing of ACTH and B-
endorphin in the rat pituitary. Acute morphine decreased intracellular cAMP, and down 
regulated PC1/3 and PC2 mRNA levels.  Chronic morphine administration in vivo 
increased PC1/3 and PC2 protein levels and intracellular cAMP levels however, it 
decreased POMC protein levels. PCs are regulated differently by the acute and chronic 
morphine administration.  The regulation of PC1/3 and PC2 correlated with intracellular 
cAMP levels (personal communication, Friedman 2007). 
26 
 
The ratio of biologically active peptide hormones (β-endorphin and ACTH) to the 
inactive prohormone POMC can be altered by regulating the processing enzymes of 
PC1/3 and PC2.  Friedman’s group hypothesized that exogenous opiates could alter 
neurohormonal levels by regulating the processing enzymes that control the ratio of 
active hormone (β-endorphin) to prohormone (POMC).  
 
Drug Addiction 
 The compulsive use of a substance resulting in physical, psychological, or social 
harm to the user and continued use despite negative consequences is called drug 
addiction (National Institute on Drug Abuse, 2007; Wallace, Mark S. and Staats, Peter S., 
2005). “Drug addiction is a brain disease that can be treated,” stated the Director of the 
National Institute on Drug Abuse Nora D. Volkow, M.D.  Physical dependence can occur 
where the body adapts to the presence of the substance, and withdrawal symptoms occur 
if use is reduced abruptly.  If higher doses of a substance must be taken to obtain the 
same initial effects, then the organism has developed tolerance.  For example, the 
protocol used in this research required dosing rats using a 75 mg pellet on Day 1 and 225 
mg (3 pellets) on Day 4 to mimic the tolerance developed over time in humans to yield 
the same analgesic effect of morphine. Other studies have been conducted using a similar 
tolerance regimen (Villar and Bhargava, 1992; Kaneto et al., 1985; Cerletti et al., 1976). 
Heroin is diacetylated morphine; a derivative that is highly abused and presents a 
major public health problem in American communities.  Elevated β-endorphin levels 
have been shown in the plasma and cerebrospinal fluid of heroin addicts that show signs 
of withdrawal (Bronstein, DM 1990).  However, the mechanisms that support opioid 
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addiction are poorly understood (Kieffer, 1999).  When an organism has reached a state 
of dysregulation in which it can no longer return to homeostasis, the transition from drug 
user to drug addict occurs according to Friedman (Personal communication, written, 
Friedman, 2007). 
 The knowledge of how and where pharmacologic agents work allows for the best 
treatment options for safety, efficacy, and tolerability.  Methodone, Buprenophine, 
Naltrexone, and Naloxone are pharmacological options available to effectively treat 
addiction to prescription opioids (NIDAinfofacts.com). 
 The current study does not examine dependence because no physical disturbances 
were recorded. Also this study does not evaluate withdrawal because an opiate antagonist 
was not administered and withdrawal symptoms were not measured. 
 
SELDI- TOF Mass Spectrometry 
  Surface Enhanced Laser Desorption Ionization Time of Flight Mass Spectrometry 
(SELDI-TOF MS) was developed by Hutchens and Yip in 1993 to determine the 
molecular masses of protein extracts and to examine protein expression patterns 
(Hutchens and Yip, 1993).  The technology can be used to describe protein-protein 
interactions, and identify biomarkers for disease.  SELDI- TOF Mass Spectrometry 
involves placing complex mixtures of proteins onto a chemically enhanced 
ProteinChip®, then washing the chip with a buffer to remove excess proteins. Proteins 
bind to the chip based on its chemical characteristics. Several forms of the chip are 
available, i.e. weak cation exchange (WCX2), strong anion exchange (SAX2), 
hydrophobic (H4), normal phase (NP1), metal binding (IMAC), and protein attachment 
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(PS20).  Using specific washing buffers, allows specific proteins to adhere to each type of 
ProteinChip permitting purification to occur on the chip instead of performing SDS-page 
and HPLC techniques. SELDI-TOF MS is helpful in detecting low molecular weight 
proteins, eliminates extensive purification processes, and it allows for faster, 
reproducible, and more efficient diagnostic tools used for screening proteins and peptides 
within tissues or body fluid samples (D.R. Cool, unpublished data) (Figure 8).    
Previously, our lab has used Ciphergen SELDI-TOF MS to analyze peptides 
hormones in specific brain regions, e.g. pituitary and hypothalamus (Hardiman et al., 
2005).  The results from those studies identified multiple β-endorphin species, e.g., 1-31, 
1-29, 1-27 and 1-26, as well as their acetylated forms. Therefore, we used this data to 
identify the region of the mass spectrum profile that we wanted to analyze for β-
























Δ Mass Amino Acid 
removed 
Sequence      
-VTLFKNAIIKNAHKKGQ* 1-31 3435 3477       
-VTLFKNAIIKNAHKKG 1-30 3307 3349 128 Q 
-VTLFKNAIIKNAHKK 1-29 3250 3292 57 G 
-VTLFKNAIIKNAHK 1-28 3122 3164 128 K 
-VTLFKNAIIKNAH 1-27 2994 3036 128 K 
-VTLFKNAIIKNA 1-26 2857 2899 137 H 
-VTLFKNAIIKN 1-25 2786 2828 71 A 
      
 
*Only the last 17 amino acids of β-endorphin are shown. All ion peaks are in daltons. 
Expected indicates expected ion peak an acetylated indicates the acetylated form of the 




β-endorphin is a peptide hormone that is preferentially cleaved from its precursor 
prohormone POMC.  Previous research has suggested the involvement of two enzymes in 
this process i.e. PC1/3 and PC2.  Furthermore, research suggests that these enzymes may 
be modulated by acute (1 day) and subacute (7 day) treatment with morphine.  The goal 
of this project was to study the effect that morphine has on β−endorphin processing 
acutely (24 hours) and subacutely (7days), in specific rat brain regions i.e. amygdala 
(AMY) ), nucleus accumbens (NA), periaqueductal gray (PAG), lateral hypothalamus 
(LH), arcuate nucleus (ARC), and paraventricular nucleus (PVN).  The hypothesis is β-
endorphin processing will not be altered in rats treated acutely with morphine, but will be 
altered in specific brain regions treated with morphine for 7days. 
 The specific aims are designed to use SELDI-TOF Mass Spectrometry to analyze 
the β-endorphin peptide hormone spectrum, and to identify and analyze specific β-
endorphin peptide hormones to discover the effect that morphine has on prohormone 
processing after 24 hours and 7days of treatment. 
 
Specific Aim: 
1.) Test the hypothesis that β-endorphin cleavage from the prohormone POMC is not 
altered in specific brain regions of rats treated acutely, i.e., 24 hours, with 
morphine. 
2.) Test the hypothesis that β-endorphin cleavage from the prohormone POMC is 
significantly altered in specific brain regions of rats treated subacutely, i.e., 7 
days, with morphine.  
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IV. MATERIALS & METHODS  
Animals 
Sprague Dawley Rats 
Studies were performed in two month old male Sprague Dawley (250-300g) rats 
that were obtained from Harlan.  Rats were housed in humidity, temperature, and light 
controlled room with free access to food and water. The animal procedures were 
performed in compliance with the National Institute of Health Guidelines for the Use of 
Animals in Research and approved by the Institutional Animal Care and Use Committee 
of Charles R. Drew University of Medicine and Sciences.  The brain extracts from these 
rats were provided by Dr. Theodore C. Friedman, Charles Drew University.  
 
Animal Treatments and Protocols 
Four to six Sprague Dawley rats were used per treatment group.  A 75mg 
morphine or placebo pellet was administered by subcutaneous implantation between the 
scapulas of the Sprague Dawley rat while under Isoflurane (Attane) anesthesia.  The 
pellets were obtained from the National Institute of Drug Abuse (NIDA).  After 
treatment, the rats were sacrificed by CO2 necrosis. Sections of the brain amygdala, 
nucleus accumbens, paraquaductual gray and hypothalamus regions were frozen, stored, 
and used for protein preparation.  
 In the acute Day 1 study, rats were treated with one morphine pellet (75mg) and 
euthanized by decapitation after 24 hours.  Sections of the brain were frozen onto 
microscope slides and stored. The specimens were incubated in 2N acetic acid until use 
for protein preparation. The purpose of this experiment was to analyze the effect of 
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morphine treatment on β-endorphin processing after 24 hours on six rat brain regions 
compared to controls.  
 In the subacute Day 7 study, rats were treated with one morphine pellet (75mg) 
on Day 0 and reimplanted with 3 morphine pellets (225mg) on Day 4, then euthanized by 
decapitation on Day 7.  Brain sections were extracted, frozen, and stored until protein 
analysis. The purpose of the Day 7 study was to determine the effect of morphine 
exposure on β-endorphin processing. The control animals received the same number of 
placebo pellets.   
 
Ciphergen Protein Chip SELDI -TOF Mass Spectrometric Analysis of Morphine 
Treated Rat Samples   
Amygdala (AMY), Nucleus accumbens (NA), Periaqueductal gray (PAG), Lateral 
hypothalamus (LH), Arcuate nucleus (ARC), and Paraventricular nucleus (PVN) rat brain 
samples were each homogenized in 0.1 N HCL.  Cell debris was removed by 
centrifugation (5 minutes at 15,000 x g).  One microgram of each sample was spotted 
onto a Weak Cation Exchange (WCX2) protein chip (Ciphergen, Palo Alto, CA) and 
allowed to dry.  Then the chip was washed with 5 ul distilled water and allowed to dry. 
The energy absorbing molecule, alpha-cyano-4-hydroxy cinnamic acid (CHCA) in 50% 
acetonitrile and 0.1% Trifluero acidic (TFA) was added to each spot and allowed to dry.  
The protein chips were analyzed on a Ciphergen SELDI- TOF Protein Biology System II 
(Ciphergen, Palo Alto, CA) with an automated spot protocol that ionized each spot four 
times over twenty different areas.  The spot was ionized initially with two laser hits at an 
intensity of 170, with the sensitivity set at 10, followed by 4 laser hits at an intensity of 
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195.  The source voltage was set at 20,000V and detector voltage at 1, 900V.  Eighty 
laser hits were averaged for each spot and a protein profile with respective masses was 
generated.  Ciphergen ProteinChip® software was used to intergrate the area under each 
peak for quantitative analysis. 
 
Statistical Analyses 
The data were expressed as the mean plus or minus the standard deviation (SD).  A two –
way analysis of variance with Bonferroni’s post hoc test and Mann-Whitney was used to 
analyze the drug treatment (placebo vs. morphine) and length of treatment (1 Day or 7 
Days) compared to the mass and intensity of the spectrum peak.  A p< 0.05 was 




Το test the hypothesis that β-endorphin processing will be altered in specific brain 
regions of rats treated with morphine, we studied peptides in the range characteristic of β-
endorphin peptide hormone using Ciphergen’s SELDI-TOF Mass Spectrometry.  We 
analyzed six brain regions associated with β-endorphin; the amygdala, nucleus 
accumbens, periaqueductal gray, lateral hypothalamus, arcuate nucleus and 
paraventricular nucleus. (Figures 2 and 3) 
 
Amygdala (AMY) Proteomic Profile 
We analyzed the Amygdala region by SELDI-TOF MS (Appendix A). While 
there were numerous ion peaks in this region we focused on nine ion peaks that were 
characteristic of β-endorphin or its processed metabolites. First, we observed that there 
was no significant difference in Placebo Day 1 or Placebo Day 7 for any of the amygdala 
peaks (Figure 9 A&B). For Morphine Day 1, the 3482 dalton peak was significantly 
lower than the same peak in Placebo Day 1 (Figure 9A). In contrast, comparison of 
Placebo Day 7 with Morphine Day 7 indicated that the 3482 peak was significantly 
higher in Morphine Day 7 compared to Placebo Day 7.  Comparison of Morphine Day 1 
with Morphine Day 7 showed two peaks i.e., 3482 and 3499, were both significantly 












Figure 9 : Amygdala Day 1 and Day 7 Studies Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the amygdala region for peptides 
characteristic of β-endorphin or its metabolites. The X-axis shows the mass/charge of the 
ion peaks in the β-endorphin range. The Y-axis indicates mean relative intensity for each 
peak, expressed in percent. Rats received 75 mg of morphine or placebo pellet implanted 
under the skin for 24 hours with replacement at 72 hours for the 7 day treament. The 
results represent the mean +/- standard deviation for N=6 (Placebo) or N=5 (Morphine). 















Table 6: Amygdala Region  
 
Mass PD1 vs. PD7 P-value MD1 vs. 
PD1 
P-value MD7 vs. PD 7 P-value MD1 vs. 
MD 7 
P-value 
3482   ↓ p<0.001 ↑ p<0.001 ↓ p<0.001 
3499       ↓ p<0.001 
 
Two peak masses, 3482 and 3499, were significantly different in the amygdala rat brain 
reigion with p<0.001. Morphine Day 1 is significantly lower than Placebo Day 1 at peak 
3482 for the amygdala. PD1, Placebo Day 1; PD7, Placebo Day 7; MD1, Morphine Day 
1; MD7, Morphine Day 7 
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Nucleus Accumbens (NA) Proteomic Profiles 
 Using SELDI-TOF MS (Appendix A) to analyze the Nucleus Accumbens area, we 
evaluated seven peaks in the β-endorphin region. The 3481 peak was significantly higher 
in Placebo Day 1 compared with Placebo Day 7 (Figure 10 A&B).  There was no 
significant difference in any of the peaks for Placebo Day 1 compared to Morphine Day 
1. The 3500 dalton ion peak was significantly higher in Morphine Day 7 compared to 
both Placebo Day 7 and Morphine Day 1 (Table 7).  
 
 Periaqueductal Gray (PAG) Proteomic Profiles 
 In the Periaqueductal gray region, eight ion peaks were identified by SELDI-TOF MS 
(Appendix A). The placebo groups showed significant differences at the 3080 and 3195 
ion peaks (Figure 11 A&B). Morphine Day 1 was significantly higher at the 3080 ion 
peak compared to Placebo Day 1. The 3195 ion peak was significantly higher in 
Morphine Day 7 compared to Placebo Day 7. Morphine Day 7 was significantly lower at 
the 3080 peak compared to Morphine Day 1. However, the 3195 ion peak was 
significantly higher for Morphine Day 7 compared to Morphine Day 1 (Table 8). 
 
Lateral Hypothalamus (LH) Proteomic Profiles 
 Morphine showed no significant difference for the six ion peaks (Figure 12 A&B) 
examined in the lateral hypothalamus for the 2700-3500 dalton region using SELDI-TOF 







Figure 10: Nucleus Accumbens Day 1 and Day 7 Study Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the nucleus accumbens region for 
peptides characteristic of β-endorphin or its metabolites. A. There were no significant 
peaks indicated for the Day 1 study.   B. The asterisk indicates significance at a p<0.001 



































3481 ↑ p<0.001       
3500     ↑ p<0.001 ↓ p<0.001 
 
The table illustrates the results from several different comparisons along with their p-
value. Two peak masses, 3481 and 3500, were significantly different in nucleus 
accumbens rat brain reigion with p<0.001. There was a significant difference at the 3481 
dalton peak in the placebo group comparison. Morphine Day 7 is significantly higher 
than Placebo Day 7 at peak 3500 for the nucleus accumbens.  Morphine Day 1 is 
significantly lower than Morphine Day 7. PD1, Placebo Day 1; PD7, Placebo Day 7; 







Figure 11: Periaqueductal Gray Day 1 and Day 7 Study Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the periaqueductal gray rat brain 
region for peptides characteristic of β-endorphin or its metabolites. A.  For the Day 1 
study, the 3080 dalton peak was significantly higher in the Morphine group compared to 
the placebo group.   B. The morphine Day 7 group at 3195 dalton peak was significantly 



























3080 ↑ p<0.01 ↑ p<0.05   ↑ p<0.001 
3195 ↓ p<0.01   ↑ p<0.05 ↓ p<0.001 
 
The table illustrates the results from comparisons of the Day 1 and Day 7 studies along 
with their p-value. Two peak masses, 3080 and 3195, were significantly different in the 
periaqueductal gray rat brain reigion. There was a significant difference at the 3080 and 
3195 dalton peaks in the placebo group comparison. Morphine Day 1 is significantly 
higher than Placebo Day 1 at peak 3080. Also, the Morphine Day 1 group was 
significantly higher than the Morphine Day 7 group. Morphine Day 7 is significantly 
higher  than Placebo Day 7. However, Morphine Day 1 is significantly lower than 
Morphine Day 7. PD1, Placebo Day 1; PD7, Placebo Day 7; MD1, Morphine Day 1; 







Figure 12: Lateral Hypothalamus Day 1 and Day 7 Study Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the lateral hypothalamus region for 
peptides characteristic of β-endorphin or its metabolites. The data indicated that there 
were no significant differences at the six ion peaks analyzed for both the Day 1 and Day 




Arcuate Nucleus (ARC) Proteomic Profiles 
 We analyzed the Arcuate nucleus region by SELDI-TOF MS (Appendix A) focusing 
on ten ion peaks within the characteristic β-endorphin region (Figure 13 A&B). The Day 
1 and Day 7 placebo groups showed significant differences at the 2976 and 3482 ion 
peaks. In contrast, there was no significant difference in the Placebo Day 1 compared to 
Morphine Day 1 or the Placebo Day 7 compared to Morphine Day 7 treatment groups. 
Comparison of the Morphine Day 1 with Morphine Day 7 showed two peaks i.e., 2976 
and 3482, that were both significantly lower in Morphine Day 7 (Table 9). 
 
Paraventricular Nucleus (PVN) Proteomic Profiles 
The proteomic profile for the Paraventricular nucleus (Appendix A) included 
eleven ion peaks that were evaluated. (Figure 14 A&B) Placebo Day 1 and Placebo Day 7 
at the 3260 peak were significantly different. In contrast, there was no significant 
difference in the Placebo Day 1 compared to Morphine Day 1 or the Placebo Day 7 
compared to Morphine Day 7 treatment groups. Morphine Day 7 was significantly higher 
at peaks 2831, 2860, 3260, and 3305 compared to Morphine Day 1.  In addition, peak 












Figure 13: Arcuate Nucleus Day 1 and Day 7 Study Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the arcuate nucleus of the rat brain 
region for peptides characteristic of β-endorphin or its metabolites. The results showed 






























2976 ↑ p<0.01     ↑ p<0.01 
3482 ↑ p<0.001     ↑ p<0.001 
 
The table illustrates the results from several comparisons of the Day 1 and Day 7 studies 
along with their p-values. Two peak masses, 2976 and 3482, were significantly different 
in the arcuate nucleus of the rat brain reigion used to analyzed the β-endorphin region. 
There was a significant difference at the  2976 and 3482 dalton peaks in the placebo 
group comparison. There were no significant ion peaks indicated in the β-endorphin 
region for the Day 1 and Day 7 studies. Morphine Day 1 is significantly higher than 
Morphine Day 7 at both 2976 and 3482.  PD1, Placebo Day 1; PD7, Placebo Day 7; 









Figure 14: Paraventricular Nucleus Day 1 and Day 7 Study Placebo vs. Morphine 
SELDI-TOF mass spectrometry was used to analyze the paraventricular nuclues region 
for peptides characteristic of β-endorphin or its metabolites. A. There were no significant 



















2831       ↓ p<0.05 
2860       ↓ p<0.05 
3079       ↑ p<0.01 
3260 ↓ p<0.001     ↓ p<0.001 
3305       ↓ p<0.05 
 
The table illustrates the results from several comparisons of the Day 1 and Day 7 studies 
along with their p-values. Several peaks were significantly different in the paraventricular 
nucleus of  the rat brain reigion used to analyzed the β-endorphin region. There was a 
significant difference at the 3260 dalton peak in comparing the  placebo groups from Day 
1 and Day 7. There were no significant ion peaks indicated in the B-endorphin region for 
the Day 1 and Day 7 studies. Morphine Day 1 is significantly lower than Morphine Day 7 
at 2831,2860, 3260, and 3305. However, Morphine Day 1 is significantly higher than 
Morphine Day at peak 3079.  PD1, Placebo Day 1; PD7, Placebo Day 7; MD1, Morphine 
Day 1; MD7, Morphine Day 7 
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Table 10: Observed ion peaks and predicted β-endorphin species located in various 







β-end species  
 
AMY 3482 1-31 
AMY 3499 1-31 
ARC 2976 1-27 
ARC 3482 1-31 
NA 3481 1-31 
NA 3500 1-31 
PAG 3080 1-27 or 1-28 
PAG 3195 1-28 
PVN 2831 1-25 
PVN 2860 1-26 
PVN 3079 1-27 or 1-28 
PVN 3260 1-29 
PVN 3305 1-30 
 
The cleaved forms of β-endorphin may have reduced biological activity compared to β-
endorphin1-31. AMY, Amgdala; ARC, Arcuate nucleus; NA, Nucleus Accumbens, PAG, 




  Our goal was to determine the effects of morphine on β-endorphin processing by 
examining the peptide hormone spectrum in specific regions of the rat brain. Alterations 
in the levels of PC1 and PC2 enzymes would modify the ratio of active peptide 
hormones, in the pituitary and hypothalamus, to inactive precursors.  According to a 
personal written communication from Ying Nie and T.C. Friedman, modifying the levels 
of proteolytic cleaving enzymes, may possibly occur to assist in restoring a hormonal 
homeostasis to the cell. This modification may help regulate the amount of 
neurotransmitters released in response to an opioid agonist or antagonist (personal 
communication, written, March 2007).   
β-endorphin1-31 is the biologically active opioid form of the endogenous peptide. 
Previous experiments by Jaffe et al. (1994) and Roullie et al. (1995) showed that the PC2 
enzyme is required for C-terminal processing of β-endorphin.  This processing generates 
shortened forms of β-endorphin that have reduced biological activity (Jaffe et al., 1994; 
Rouille et al., 1995).  Although the modulation of PC2 protein and mRNA by morphine 
has been determined in previous studies, its activity on endorphin processing has not been 
elucidated.  One reason for this is that β-endorphin is a small peptide that cannot be 
efficiently resolved on protein gels.  Radioimmunoassays using specific antibodies lack 
specificity with similar substrates.  Thus, we chose to use the mass spectrometric 
technique of SELDI-TOF mass spectrometry to analyze β-endorphin in specific brain 
regions that are known to be affected by morphine.  
The first question to be answered was whether acute administration of morphine 
would have an effect on β-endorphin processing in specific brain regions.  Acute 
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morphine administration showed no significant effect on β-endorphin processing in the 
lateral hypothalamus (Table 12).  Likewise, there was no significant effect of morphine 
on β-endorphin processing for the acute 1 Day study in the arcuate nucleus, lateral 
hypothalamus, nucleus accumbens, and paraventricular nucleus. This result was 
somewhat surprising because the hypothalamus contains mu-receptors to which morphine 
can bind; therefore, an effect was expected (Mansour et al., 1994; Zhou et al., 2006).  
However, the results are not outside of the scope of thought when considering the timing 
of prohormone processing enzyme expression and prohormone secretion. That is, 
prohormones and mature peptide hormones can reside within secretory granules inside of 
the cell for up to 3 days. Thus, a short-term change in the expression of processing 
enzyme (PC1/3 or PC2) or even prohormone (POMC) would not be observed until at 
least 3 days after the change in expression. The secretory granules will replenish with 
fresh hormone after 3 days and changes occurring at the enzyme level would begin. 
However, in our study, we did observe a change in processing of b-endorphin within 24 
hours. This suggests the possibility that b-endorphin may be replenished faster or that 
other factors are involved in β-endorphin processing than PC2.   
In contrast to the acute time points, we also wanted to determine if a longer, 
subacute time point could provide a different outcome for β-endorphin processing. In 
previous studies, PC2 was up-regulated after 7 days of morphine treatment (unpublished 
data, Friedman, 2007).  In our study, there was no significant effect on β-endorphin 
processing for the subacute 7 day study in the arcuate nucleus, lateral hypothalamus, and 
paraventricular nucleus. There are at least three reasons for this outcome.  
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First, PC2 expression may not have been affected by morphine in these regions. 
This would only be the case if morphine did not interact with receptors in these regions. 
However, opioid receptors do exist in these regions and thus, we believe that PC2 
expression levels should have been affected. Second, PC2 expression could have been 
down regulated early and then slowly over the course of seven days, normal expression 
levels may have been re-established. If this were the case, then changes in β-endorphin 
expression levels, or for that matter, processing, would be observed. This has been 
proposed by Dr. Friedman as a mechanism for morphine effects on drug abuse for a 
parallel study on PC2 expression. Third, while the expression of PC2 may have been 
modulated, the expression of POMC, the precursor to β-endorphin, might have been up 
regulated. Direct evidence for this can be found in preliminary unpublished data from the 
Friedman lab. Our data support this hypothesis and mechanism. Further studies showed a 
down regulation of endogenous POMC mRNA in the rat hypothalamus was observed 
after 7 day morphine administration in studies performed by the Bronstein laboratory. 
(Bronstein et al., 1990).  
Perhaps even more surprising, was the significant differences observed in the 
placebo groups of the arcuate nucleus, nucleus accumbens, periaqueducatal gray, and 
paraventricular nucleus. The Day1 treatment had its own placebo group for its study 
while the Day 7 treatment had another set of rats used in its study. We were expecting the 
placebo groups to show no significant difference between placebo Day 1 and placebo 
Day 7. The individual differences within the species may account for the differences 
observed at specific peaks within the ARC, NA, PAG, and PVN.  
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The arcuate nucleus is located in the mediobasal hypothalamus adjacent to the 
third ventricle and the median eminence.  In rodents, the arcuate nucleus is referred to as 
the infunibular nucleus.  The arcuate nucleus contains neurons with nerve endings located 
in the median eminence that release dopamine and inhibit prolactin secretion and 
gonadotropin releasing hormone. The arcuate nucleus of the hypothalamus and its 
efferent β-endorphinergic fibers are involved in the descending pathway from the nucleus 
accumbens to the Periaquaductal gray (PAG) (Yu L., 1989). Cells in the PAG contain 
opiate peptides receptors which upon injections of morphine-like substances can reduce 
pain by turning on the smaller inhibitory PAG neurons in the midbrain. We observed an 
increase in two β -endorphin cleavage peptides in the PAG region, suggesting that they 
were down regulated and that in the absence of morphine, pain perception would be 
higher. There was no change observed between morphine and placebo rat β-endorphin in 
the arcuate nuclear tissue.  
The amygdala is a subcortical complex composed of 13 nuclei which help to 
control autonomic responses associated with fear, emotional responses, and hormonal 
secretions.  Various amygadaloid nuclei differ in the type of functional systems they 
influence. Outputs from the lateral nucleus project into the cortical areas.  The basal 
nucleus provides information to the nucleus accumbens, forntal cortex and medial 
temporal lobe memory system.  The central nucleus projects to the hypothalamus, 
midbrain, and bed nucleus of stria terminalis.  The dorso medial part of the amygdala is 
one of the most important brain structures contributing to modulation of pain.  The 
amygdala contains high concentrations of opioid receptors (Sabetkasaei M., 2007). The 
acute decrease in β -endorphin1-31 and increase after 7 days of morphine treatment 
54 
 
strongly suggest that β -endorphin was being down regulated acutely, followed by an 
upregulation. However, the increased full-length β -endorphin1-31 also suggest that it 
was not being degraded or cleaved to β-endorphin1-29 or 1-27. The results suggest that 
hormonal secretion, fear and emotional responses may be attenuated in morphine treated 
animals.  
Likewise, an increase in β-endorphin1-31 in the nucleus accumbens region 
suggests a buildup over the 7 day time period, but no breakdown. This would suggest that 
the reward center in this region was being overstimulated by morphine and that β-
endorphin was not being released. This could suggest that the rat was becoming addicted 
to morphine, since the NA region is part of the addiction region of the brain.  
We found that β-endorphin in specific brain regions were significantly affected at 
specific peaks within the presumed β-endorphin region. The data strongly suggest that 
PC2 was involved in subsequent processing of β-endorphin1- 31 (Table 10).   Previous 
evidence from the Cool Lab indicates that when PC2 was knocked out in mice, β-
endorphin was not processed to smaller forms (Hardiman et al., 2005; Hardiman, 2004).  
This is in contrast to PC1/3 knockout studies where we observed no change in β-
endorphin processing in mice lacking PC1/3 (Figure 15). Thus, we concluded that PC2 is 
involved in β-endorphin processing but not PC1/3.  
Withdrawal, dependence and tolerance have previously been shown in rats that 
were implanted with morphine pellets for up to 7 days. After 3 days, dependence and 
tolerance peaked then gradually declined over time. (Cicero and Meyer, 1973; Tilson et 
al., 1973). This data supports the present study protocol wherein rats received one 
morphine pellet (75mg) on Day 0 and were reimplanted with 3 morphine pellets (225mg) 
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on Day 4.  However, the current study did not examine dependence because no physical 
disturbances were recorded. Also, this study does not monitor for withdrawal symptoms 
because an opiate antagonist was not administered and withdrawal symptoms were not 
measured.  
 In summary, the experiment explored the affects of morphine-treatment on the 
processing of β-endorphin1-31 after 24 hours and 7 day exposure. Altering the hormonal 
state of the cell can assist it in maintaining homeostasis by controlling the ratio of active 
hormone (β-endorphin) to prohormones (POMC precursor). The conversion of β-LPH to 
β−endorphin in the hypothalamus and amygdala is impaired in mice lacking the PC2 
enzyme. This impairment causes β-endorphin to increase in the hypothalamus and 




Table 12: Comparisons of Placebo and Morphine groups in the Acute Day1 and  
Subacute Day 7  
 Brain Regions 
Comparisons LH ARC NA PVN PAG AMY 
Acute Day 1  
(MD1 vs. PD1) 
NS NS NS NS 3080↑ 3482↓ 
Subacute Day 7  
(MD7 vs. PD7) 
NS NS 3500↑ NS 3195↑ 3482↑ 
Placebo 
(PD1 vs. PD7) 
NS 2976 ↑, 
3482 ↑ 
3481↑ 3260↓ 3080↑, 3195↓ NS 
Morphine 








3080↑, 3195↓ 3482↓, 3499↓ 
*Table Interpretation Example-Morphine Day 1 is significantly lower (↓) than Placebo 
Day 1 at peak 3482 for the Amygdala. (2-Way ANOVA, p<0.05 is significant)  PD1, 













Understanding the regulation of POMC, PC1, and PC2 may lead to a better 
understanding of opiate drug abuse and addiction.  Changes in processing enzymes due to 
opiate exposure may alter the levels of biologically active peptide hormones that control 
physiological actions observed in drug addiction.  Drug addiction is not only a social 
problem, but a brain disease that affects behavior. Prohormone processing may be an 
adaptive response regulated by acute and chronic opiate exposure.  More studies should 
examine the physiological actions of altering PC levels after chronic opiate intake, how 
PC1 and PC2 may alter other prohormone systems, and how the regulation of PC1 and 
PC2 by glucose, cytokines, and thyroid hormones affect the ratio of prohormones to 
active hormones. Also, understanding how opiates cause analgesia and lead to tolerance 
and dependence can further our scientific knowledge of ways to create better pain 
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A. Peptide Profile Spectrums  
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B.   Number of Animals per Treatment and Day  
Brain Region Placebo Day 1 Morphine Day 1 Placebo Day 7 Morphine Day 7 
Amygdala 6 5 5 5 
Arcuate Nucleus 6 5 5 5 
Lateral Hypothalamus 6 5 5 5 
Nucleus Accumbens 6 5 5 5 
Periaqueductal gray  6 5 5 5 
Paraventricular Nucleus  6 5 4 4 
C.   Statistical Data Representing F-values for Each Brain Region 
Source of Variation AMY ARC LH NA PAG PVN 
Interaction 2.716 2.654 0.895 6.715 7.231 4.416 
Treatment and Day 15.93 15.51 1.45 10.41 2.53 3.32 
Mass 54.58 14.36 9.39 16.11 15.19 7.77 
 
 
 
 
